Silvana Battaglia Sells 5,000 Shares of Cencora, Inc. (NYSE:COR) Stock

Cencora, Inc. (NYSE:COR) EVP Silvana Battaglia sold 5,000 shares of the stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $242.24, for a total value of $1,211,200.00. Following the completion of the sale, the executive vice president now owns 15,374 shares of the company’s stock, valued at approximately $3,724,197.76. This trade represents a 24.54 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Silvana Battaglia also recently made the following trade(s):

• On Friday, December 20th, Silvana Battaglia sold 1,678 shares of Cencora stock. The shares were sold at an average price of $228.72, for a total value of $383,792.16.

Cencora Trading Up 2.6 %

NYSE COR opened at $250.59 on Wednesday. Cencora, Inc. has a 12 month low of $214.77 and a 12 month high of $262.26. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. The stock’s fifty day moving average price is $240.27 and its 200-day moving average price is $237.56. The stock has a market cap of $48.60 billion, a P/E ratio of 35.65, a P/E/G ratio of 1.31 and a beta of 0.49.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. As a group, equities analysts forecast that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 3rd. Investors of record on Friday, February 14th will be issued a $0.55 dividend. The ex-dividend date is Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a yield of 0.88%. Cencora’s payout ratio is currently 31.29%.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on COR. JPMorgan Chase & Co. boosted their price objective on shares of Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. UBS Group upped their target price on Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Wells Fargo & Company lifted their price target on Cencora from $237.00 to $251.00 and gave the company an “equal weight” rating in a research report on Wednesday, January 29th. Robert W. Baird upped their price target on Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. Finally, Mizuho assumed coverage on Cencora in a research report on Wednesday, December 4th. They set an “outperform” rating and a $280.00 price objective for the company. Two research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $277.90.

Hedge Funds Weigh In On Cencora

Several hedge funds and other institutional investors have recently added to or reduced their stakes in COR. JFS Wealth Advisors LLC raised its stake in shares of Cencora by 63.0% in the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company’s stock worth $27,000 after purchasing an additional 46 shares during the last quarter. Banque Transatlantique SA bought a new stake in Cencora in the 4th quarter worth about $29,000. SBI Securities Co. Ltd. purchased a new position in Cencora in the 4th quarter worth about $30,000. Concord Wealth Partners bought a new position in Cencora during the 3rd quarter valued at about $30,000. Finally, Kentucky Trust Co purchased a new stake in shares of Cencora during the 4th quarter valued at about $33,000. 97.52% of the stock is owned by institutional investors.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.